← Leaderboards
Yuqing E Chen
University Of Michigan At Ann Arbor
$44,993,151
Attributed
$53,718,717
Total exposure
22
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$53,718,717 · 22
By mechanism
R01$51,546,712 · 18
T32$983,632 · 1
R24$776,504 · 1
R21$411,869 · 1
S06$0 · 1
Top collaborators
- Renzhi Han6 shared
- Peter X Ma6 shared
- Minerva T Garcia-Barrio4 shared
- Anna Schwendeman4 shared
- Gorav Ailawadi3 shared
- Donald S Likosky3 shared
- Ida Liisa Surakka2 shared
- Zachary Thomas Freeman1 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Philip C Hanna$1,847,321
- Lin Chang$4,634,182
- Patricio Escalante$1,961,604
- Luis Villacorta$2,232,929
Others in their field
Top investigators on “Cardiovascular Diseases”
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$145,558,149
- Judith S. Currier · University Of California Los Angeles$143,001,230
- David M Nathan · Massachusetts Institute Of Technology$141,671,512
- John M Lachin · George Washington University$139,991,329
- Judith S Hochman · New York University School Of Medicine$112,514,057
Research focus
Cardiovascular DiseasesIn VitroIn VivoMediatingBlood VesselsAtherosclerosisAnimal ModelLoss Of FunctionCardiovascular SystemPathway InteractionsKnock-OutSignal TransductionProteinsBaseRegulationPharmaceutical PreparationsInsightNovel TherapeuticsEventCellsMouse ModelResponseMolecularMediator Of Activation Protein
Grant awards (106)
Using genetics to discover mechanisms of abdominal aortic aneurysm$779,872
R01 · FY2025 · HL · contact PI
National Center of Rabbit Models for Translational Research$776,504
R24 · FY2025 · OD · contact PI
Nitro-Fatty Acids and Cardiovascular Disease$720,438
R01 · FY2025 · HL · contact PI
Targeted editing of ASGR1 for cardiovascular diseases$707,525
R01 · FY2025 · HL
Browning of perivascular adipose tissue protects against thoracic aortic aneurysm$586,229
R01 · FY2025 · HL · contact PI
Surgeon Scientist Training in Cardiac Diseases$388,059
T32 · FY2025 · HL · contact PI
Using genetics to discover mechanisms of abdominal aortic aneurysm$779,872
R01 · FY2024 · HL · contact PI
Targeted editing of ASGR1 for cardiovascular diseases$722,150
R01 · FY2024 · HL
Nitro-Fatty Acids and Cardiovascular Disease$706,029
R01 · FY2024 · HL · contact PI
Development of gene editing based therapy for cardiovascular diseases$689,276
R01 · FY2024 · HL · contact PI
KLF14 and Cardiovascular Disease$606,200
R01 · FY2024 · HL · contact PI
Browning of perivascular adipose tissue protects against thoracic aortic aneurysm$574,504
R01 · FY2024 · HL · contact PI
Surgeon Scientist Training in Cardiac Diseases$396,201
T32 · FY2024 · HL · contact PI
Nitro-Fatty Acids and Cardiovascular Disease$720,438
R01 · FY2023 · HL · contact PI
Development of gene editing based therapy for cardiovascular diseases$703,344
R01 · FY2023 · HL · contact PI
KLF14 and Cardiovascular Disease$618,571
R01 · FY2023 · HL · contact PI
Browning of perivascular adipose tissue protects against thoracic aortic aneurysm$586,229
R01 · FY2023 · HL · contact PI
Surgeon Scientist Training in Cardiac Diseases$199,372
T32 · FY2023 · HL · contact PI
IDOL and dyslipidemia in cardiovascular diseases$773,938
R01 · FY2022 · HL · contact PI
Using genetics to discover mechanisms of myocardial infarction$721,541
R01 · FY2022 · HL · contact PI
Nitro-Fatty Acids and Cardiovascular Disease$720,438
R01 · FY2022 · HL · contact PI
Development of gene editing based therapy for cardiovascular diseases$703,344
R01 · FY2022 · HL · contact PI
KLF14 and Cardiovascular Disease$618,571
R01 · FY2022 · HL · contact PI
Browning of perivascular adipose tissue protects against thoracic aortic aneurysm$586,229
R01 · FY2022 · HL · contact PI
IDOL and dyslipidemia in cardiovascular diseases$773,938
R01 · FY2021 · HL · contact PI
Using genetics to discover mechanisms of myocardial infarction$754,360
R01 · FY2021 · HL · contact PI
Development of gene editing based therapy for cardiovascular diseases$717,344
R01 · FY2021 · HL · contact PI
KLF14 and Cardiovascular Disease$618,571
R01 · FY2021 · HL · contact PI
IDOL and dyslipidemia in cardiovascular diseases$773,938
R01 · FY2020 · HL · contact PI
Using genetics to discover mechanisms of myocardial infarction$754,912
R01 · FY2020 · HL · contact PI
Two-stage miRNA delivering scaffolds for patient-originated cells to regenerate blood vessels$746,181
R01 · FY2020 · HL · contact PI
KLF14 and Atherosclerosis$706,887
R01 · FY2020 · HL · contact PI
The Role of TM6SF2 in Cardiovascular Disease$557,853
R01 · FY2020 · HL · contact PI
IDOL and dyslipidemia in cardiovascular diseases$773,938
R01 · FY2019 · HL · contact PI
Two-stage miRNA delivering scaffolds for patient-originated cells to regenerate blood vessels$757,881
R01 · FY2019 · HL
Using genetics to discover mechanisms of myocardial infarction$754,912
R01 · FY2019 · HL · contact PI
KLF14 and Atherosclerosis$706,887
R01 · FY2019 · HL · contact PI
The Role of TM6SF2 in Cardiovascular Disease$557,853
R01 · FY2019 · HL · contact PI
PPAR-gamma and Vascular Disease$387,500
R01 · FY2019 · HL · contact PI
Two-stage miRNA delivering scaffolds for patient-originated cells to regenerate blood vessels$765,149
R01 · FY2018 · HL
MPO, HDL Dysfunction and Cardiovascular Disease$717,455
R01 · FY2018 · HL · contact PI
KLF14 and Atherosclerosis$705,755
R01 · FY2018 · HL · contact PI
The Role of TM6SF2 in Cardiovascular Disease$557,853
R01 · FY2018 · HL · contact PI
PPAR-gamma and Vascular Disease$387,500
R01 · FY2018 · HL · contact PI
Two-stage miRNA delivering scaffolds for patient-originated cells to regenerate blood vessels$763,098
R01 · FY2017 · HL
MPO, HDL Dysfunction and Cardiovascular Disease$716,838
R01 · FY2017 · HL · contact PI
KLF14 and Atherosclerosis$702,356
R01 · FY2017 · HL · contact PI
The Role of TM6SF2 in Cardiovascular Disease$556,958
R01 · FY2017 · HL · contact PI
PPAR-gamma and Vascular Disease$387,500
R01 · FY2017 · HL · contact PI
MPO, HDL Dysfunction and Cardiovascular Disease$716,838
R01 · FY2016 · HL · contact PI
CETP and HDL Function in Cardiovascular Diseases$620,011
R01 · FY2016 · HL · contact PI
PPAR-gamma and Vascular Disease$387,500
R01 · FY2016 · HL · contact PI
MPO, HDL Dysfunction and Cardiovascular Disease$716,838
R01 · FY2015 · HL · contact PI
CETP and HDL Function in Cardiovascular Diseases$610,711
R01 · FY2015 · HL · contact PI
Regenerating Blood Vessels Using iPS Cells$517,050
R01 · FY2015 · HL
PPAR-gamma and Vascular Lesion Formation$382,918
R01 · FY2015 · HL · contact PI
CETP and HDL Function in Cardiovascular Diseases$607,612
R01 · FY2014 · HL · contact PI
Regenerating Blood Vessels Using iPS Cells$523,937
R01 · FY2014 · HL
Nitro-Fatty Acids and Nrf2 in Vascular Remodeling$515,414
R01 · FY2014 · HL · contact PI
PPAR-gamma and Vascular Lesion Formation$380,975
R01 · FY2014 · HL · contact PI
Nitroalkene-Mediated Vascular Protection and Ischemic Stroke$336,753
R01 · FY2014 · NS · contact PI
CETP and HDL Function in Cardiovascular Diseases$590,250
R01 · FY2013 · HL · contact PI
Regenerating Blood Vessels Using iPS Cells$544,049
R01 · FY2013 · HL
Nitro-Fatty Acids and Nrf2 in Vascular Remodeling$500,689
R01 · FY2013 · HL · contact PI
PPAR-gamma and Vascular Lesion Formation$370,090
R01 · FY2013 · HL · contact PI
CRP Biology and Vascular Disease$346,396
R01 · FY2013 · HL · contact PI
Nitroalkene-Mediated Vascular Protection and Ischemic Stroke$328,251
R01 · FY2013 · NS · contact PI
Nitro-Fatty Acids and Nrf2 in Vascular Remodeling$525,933
R01 · FY2012 · HL · contact PI
PPAR-gamma and Vascular Lesion Formation$388,750
R01 · FY2012 · HL · contact PI
Nitroalkenes and Blood Pressure Regulation$367,360
R01 · FY2012 · HL · contact PI
CRP Biology and Vascular Disease$364,401
R01 · FY2012 · HL · contact PI
Nitroalkene-Mediated Vascular Protection and Ischemic Stroke$340,156
R01 · FY2012 · NS · contact PI
Nitro-Fatty Acids and Nrf2 in Vascular Remodeling$525,933
R01 · FY2011 · HL · contact PI
Nitroalkenes and Blood Pressure Regulation$433,068
R01 · FY2011 · HL · contact PI
PPAR-gamma and Vascular Lesion Formation$387,500
R01 · FY2011 · HL · contact PI
CRP Biology and Vascular Disease$368,611
R01 · FY2011 · HL · contact PI
Nitroalkene-Mediated Vascular Protection and Ischemic Stroke$340,156
R01 · FY2011 · NS · contact PI
Nitro-Fatty Acids and Nrf2 in Vascular Remodeling$541,130
R01 · FY2010 · HL · contact PI
Nitroalkenes and Blood Pressure Regulation$458,103
R01 · FY2010 · HL · contact PI
PPARgamma and Vascular Lesion Formation$454,100
R01 · FY2010 · HL · contact PI
CRP Biology and Vascular Disease$369,125
R01 · FY2010 · HL · contact PI
Nitroalkenes and Blood Pressure Regulation$24,783
R01 · FY2010 · HL · contact PI
PPARgamma and Vascular Lesion Formation$454,100
R01 · FY2009 · HL · contact PI
Nitroalkenes and Blood Pressure Regulation$371,828
R01 · FY2009 · HL · contact PI
CRP Biology and Vascular Disease$369,624
R01 · FY2009 · HL · contact PI
MicroRNA and smooth muscle cell differentiation$223,006
R21 · FY2009 · HL · contact PI
Nitroalkenes and Blood Pressure Regulation$372,066
R01 · FY2008 · HL · contact PI
PPARgamma and Vascular Lesion Formation$368,980
R01 · FY2008 · HL · contact PI
MicroRNA and smooth muscle cell differentiation$188,863
R21 · FY2008 · HL · contact PI
PPARgamma and Vascular Lesion Formation$85,120
R01 · FY2008 · HL · contact PI
PPARgamma and Vascular Lesion Formation$368,980
R01 · FY2007 · HL · contact PI
PPAR-delta in obesity-related vascular remodeling$360,308
R01 · FY2007 · HL · contact PI
PPARgamma and Vascular Lesion Formation$30,400
R01 · FY2007 · HL · contact PI
PPARgamma and Vascular Lesion Formation$473,059
R01 · FY2006 · HL · contact PI
PPAR-delta in obesity-related vascular remodeling$346,658
R01 · FY2006 · HL · contact PI
PPARgamma and Vascular Lesion Formation$118,059
R01 · FY2006 · HL · contact PI
PPAR-delta in obesity-related vascular remodeling$478,624
R01 · FY2005 · HL
The Role of PPAR-gamma in Vascular Lesion Formation$421,946
R01 · FY2005 · HL
The Role of PPAR-gamma in Vascular Lesion Formation$419,376
R01 · FY2004 · HL
PPAR-delta in obesity-related vascular remodeling$355,000
R01 · FY2004 · HL
PPAR-delta in obesity-related vascular remodeling$110,821
R01 · FY2004 · HL
The Role of PPAR-gamma in Vascular Lesion Formation$487,881
R01 · FY2003 · HL
The Role of PPAR-gamma in Vascular Lesion Formation$320,625
R01 · FY2002 · HL
The Role of PPAR-gamma in Vascular Lesion Formation$71,000
R01 · FY2002 · HL
The Role of PPAR-gamma in Vascular Lesion Formation$48,711
R01 · FY2002 · HL
PPARdelta in Vascular Smooth Muscle Cells$0
S06 · FY2002 · GM